JP4353639B2 - 二本鎖ｒｎａ阻害を用いる遺伝子機能の評価 - Google Patents

二本鎖ｒｎａ阻害を用いる遺伝子機能の評価 Download PDF

Info

Publication number
JP4353639B2
JP4353639B2 JP2000558236A JP2000558236A JP4353639B2 JP 4353639 B2 JP4353639 B2 JP 4353639B2 JP 2000558236 A JP2000558236 A JP 2000558236A JP 2000558236 A JP2000558236 A JP 2000558236A JP 4353639 B2 JP4353639 B2 JP 4353639B2
Authority
JP
Japan
Prior art keywords
promoter
ssp
plant
dna
dna sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2000558236A
Other languages
English (en)
Japanese (ja)
Other versions
JP2002519072A (ja
JP2002519072A5 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html
Inventor
ヘールト・プラエティンク
クリスト・プラッテーウ
カテリン・モルティエル
ティエリー・ボゲール
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Devgen NV
Original Assignee
Devgen NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26313977&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP4353639(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB9814536.0A external-priority patent/GB9814536D0/en
Application filed by Devgen NV filed Critical Devgen NV
Publication of JP2002519072A publication Critical patent/JP2002519072A/ja
Publication of JP2002519072A5 publication Critical patent/JP2002519072A5/ja
Application granted granted Critical
Publication of JP4353639B2 publication Critical patent/JP4353639B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1079—Screening libraries by altering the phenotype or phenotypic trait of the host
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/02—Preparation of hybrid cells by fusion of two or more cells, e.g. protoplast fusion
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1093—General methods of preparing gene libraries, not provided for in other subgroups
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
    • C12N15/8216—Methods for controlling, regulating or enhancing expression of transgenes in plant cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
    • C12N15/8216—Methods for controlling, regulating or enhancing expression of transgenes in plant cells
    • C12N15/8218—Antisense, co-suppression, viral induced gene silencing [VIGS], post-transcriptional induced gene silencing [PTGS]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
    • C12N15/8241—Phenotypically and genetically modified plants via recombinant DNA technology
    • C12N15/8261—Phenotypically and genetically modified plants via recombinant DNA technology with agronomic (input) traits, e.g. crop yield
    • C12N15/8271—Phenotypically and genetically modified plants via recombinant DNA technology with agronomic (input) traits, e.g. crop yield for stress resistance, e.g. heavy metal resistance
    • C12N15/8279—Phenotypically and genetically modified plants via recombinant DNA technology with agronomic (input) traits, e.g. crop yield for stress resistance, e.g. heavy metal resistance for biotic stress resistance, pathogen resistance, disease resistance
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
    • C12N15/8241—Phenotypically and genetically modified plants via recombinant DNA technology
    • C12N15/8261—Phenotypically and genetically modified plants via recombinant DNA technology with agronomic (input) traits, e.g. crop yield
    • C12N15/8271—Phenotypically and genetically modified plants via recombinant DNA technology with agronomic (input) traits, e.g. crop yield for stress resistance, e.g. heavy metal resistance
    • C12N15/8279—Phenotypically and genetically modified plants via recombinant DNA technology with agronomic (input) traits, e.g. crop yield for stress resistance, e.g. heavy metal resistance for biotic stress resistance, pathogen resistance, disease resistance
    • C12N15/8285—Phenotypically and genetically modified plants via recombinant DNA technology with agronomic (input) traits, e.g. crop yield for stress resistance, e.g. heavy metal resistance for biotic stress resistance, pathogen resistance, disease resistance for nematode resistance
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6869—Methods for sequencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/10011—Details dsDNA Bacteriophages
    • C12N2795/10211—Podoviridae
    • C12N2795/10241—Use of virus, viral particle or viral elements as a vector
    • C12N2795/10243—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/40—Systems of functionally co-operating vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
    • C12N2830/002—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/42—Vector systems having a special element relevant for transcription being an intron or intervening sequence for splicing and/or stability of RNA
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A40/00—Adaptation technologies in agriculture, forestry, livestock or agroalimentary production
    • Y02A40/10—Adaptation technologies in agriculture, forestry, livestock or agroalimentary production in agriculture
    • Y02A40/146—Genetically Modified [GMO] plants, e.g. transgenic plants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Virology (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Breeding Of Plants And Reproduction By Means Of Culturing (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Catching Or Destruction (AREA)
JP2000558236A 1998-07-03 1999-07-02 二本鎖ｒｎａ阻害を用いる遺伝子機能の評価 Expired - Fee Related JP4353639B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GBGB9814536.0A GB9814536D0 (en) 1998-07-03 1998-07-03 Characterisation of gene function using double stranded rna inhibition
GB9814536.0 1998-07-03
GBGB9827152.1A GB9827152D0 (en) 1998-07-03 1998-12-09 Characterisation of gene function using double stranded rna inhibition
GB9827152.1 1998-12-09
PCT/EP1999/004718 WO2000001846A2 (en) 1998-07-03 1999-07-02 Characterisation of gene function using double stranded rna inhibition

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2009001591A Division JP2009112311A (ja) 1998-07-03 2009-01-07 二本鎖ｒｎａ阻害を用いる遺伝子機能の評価

Publications (3)

Publication Number Publication Date
JP2002519072A JP2002519072A (ja) 2002-07-02
JP2002519072A5 JP2002519072A5 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2008-10-23
JP4353639B2 true JP4353639B2 (ja) 2009-10-28

Family

ID=26313977

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2000558236A Expired - Fee Related JP4353639B2 (ja) 1998-07-03 1999-07-02 二本鎖ｒｎａ阻害を用いる遺伝子機能の評価
JP2009001591A Pending JP2009112311A (ja) 1998-07-03 2009-01-07 二本鎖ｒｎａ阻害を用いる遺伝子機能の評価
JP2013186110A Expired - Fee Related JP5847776B2 (ja) 1998-07-03 2013-09-09 二本鎖ｒｎａ阻害を用いる遺伝子機能の評価

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2009001591A Pending JP2009112311A (ja) 1998-07-03 2009-01-07 二本鎖ｒｎａ阻害を用いる遺伝子機能の評価
JP2013186110A Expired - Fee Related JP5847776B2 (ja) 1998-07-03 2013-09-09 二本鎖ｒｎａ阻害を用いる遺伝子機能の評価

Country Status (27)

Country Link
US (3) US20030061626A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EP (5) EP2374901A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP (3) JP4353639B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
KR (4) KR20040066200A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CN (3) CN1198938C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AT (2) ATE419383T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU (1) AU769223B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BR (1) BR9911802A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CA (2) CA2332619C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CY (2) CY1108920T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CZ (2) CZ303494B6 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DE (5) DE29924299U1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DK (2) DK1484415T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ES (2) ES2320527T5 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
GB (4) GB9827152D0 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
HU (1) HU230602B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IL (3) IL140467A0 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IN (2) IN2001DE00006A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IS (1) IS2816B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
MX (1) MX234065B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NO (1) NO327729B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NZ (1) NZ509182A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PL (3) PL213379B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PT (2) PT1484415E (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
RU (1) RU2240349C2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
WO (1) WO2000001846A2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ZA (1) ZA200007653B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Families Citing this family (256)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6506559B1 (en) 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
KR20010042069A (ko) * 1998-03-20 2001-05-25 베니텍 오스트레일리아 리미티드 유전자 발현 조절방법
AUPP249298A0 (en) * 1998-03-20 1998-04-23 Ag-Gene Australia Limited Synthetic genes and genetic constructs comprising same I
GB9827152D0 (en) * 1998-07-03 1999-02-03 Devgen Nv Characterisation of gene function using double stranded rna inhibition
CA2361201A1 (en) * 1999-01-28 2000-08-03 Medical College Of Georgia Research Institute, Inc. Composition and method for in vivo and in vitro attenuation of gene expression using double stranded rna
DE19956568A1 (de) 1999-01-30 2000-08-17 Roland Kreutzer Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens
US7601494B2 (en) 1999-03-17 2009-10-13 The University Of North Carolina At Chapel Hill Method of screening candidate compounds for susceptibility to biliary excretion
CN1375004A (zh) * 1999-04-21 2002-10-16 惠氏公司 抑制多核苷酸序列的功能的方法和组合物
US20040138168A1 (en) * 1999-04-21 2004-07-15 Wyeth Methods and compositions for inhibiting the function of polynucleotide sequences
US6924109B2 (en) * 1999-07-30 2005-08-02 Agy Therapeutics, Inc. High-throughput transcriptome and functional validation analysis
US6423885B1 (en) 1999-08-13 2002-07-23 Commonwealth Scientific And Industrial Research Organization (Csiro) Methods for obtaining modified phenotypes in plant cells
CA2386270A1 (en) 1999-10-15 2001-04-26 University Of Massachusetts Rna interference pathway genes as tools for targeted genetic interference
GB9927444D0 (en) * 1999-11-19 2000-01-19 Cancer Res Campaign Tech Inhibiting gene expression
US7829693B2 (en) 1999-11-24 2010-11-09 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of a target gene
DE10100586C1 (de) 2001-01-09 2002-04-11 Ribopharma Ag Verfahren zur Hemmung der Expression eines Ziegens
GB9930691D0 (en) * 1999-12-24 2000-02-16 Devgen Nv Improvements relating to double-stranded RNA inhibition
US8202979B2 (en) 2002-02-20 2012-06-19 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid
US8273866B2 (en) 2002-02-20 2012-09-25 Merck Sharp & Dohme Corp. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (SINA)
US7491805B2 (en) 2001-05-18 2009-02-17 Sirna Therapeutics, Inc. Conjugates and compositions for cellular delivery
US7833992B2 (en) 2001-05-18 2010-11-16 Merck Sharpe & Dohme Conjugates and compositions for cellular delivery
US8202846B2 (en) 2000-03-16 2012-06-19 Cold Spring Harbor Laboratory Methods and compositions for RNA interference
AU2001245793A1 (en) 2000-03-16 2001-09-24 Cold Spring Harbor Laboratory Methods and compositions for rna interference
DK1309726T4 (en) 2000-03-30 2019-01-28 Whitehead Inst Biomedical Res RNA Sequence-Specific Mediators of RNA Interference
GB2362383B (en) * 2000-05-19 2003-12-31 Devgen Nv Gene expression system
GB0012229D0 (en) 2000-05-19 2000-07-12 Devgen Nv Lipid uptake assays
US7083947B2 (en) 2000-05-19 2006-08-01 Devgen Nv Assay techniques using nematode worms
GB0012233D0 (en) * 2000-05-19 2000-07-12 Devgen Nv Vector constructs
AU2001275474A1 (en) * 2000-06-12 2001-12-24 Akkadix Corporation Materials and methods for the control of nematodes
US20030190635A1 (en) * 2002-02-20 2003-10-09 Mcswiggen James A. RNA interference mediated treatment of Alzheimer's disease using short interfering RNA
DK2813582T3 (en) 2000-12-01 2017-07-31 Max-Planck-Gesellschaft Zur Förderung Der Wss E V Small RNA molecules that mediate RNA interference
US7767802B2 (en) 2001-01-09 2010-08-03 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of anti-apoptotic genes
US7423142B2 (en) 2001-01-09 2008-09-09 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of anti-apoptotic genes
BR0206690A (pt) * 2001-01-25 2006-01-17 Virxsys Corp Processos para a identificação da função do gene, para alteração da expressão de fatores celulares e para alteração do fenótipo de célula
CA2429397C (en) 2001-01-26 2014-06-03 Commonwealth Scientific And Industrial Research Organisation Methods and means for producing efficient silencing construct using recombinational cloning
US20020132257A1 (en) 2001-01-31 2002-09-19 Tony Giordano Use of post-transcriptional gene silencing for identifying nucleic acid sequences that modulate the function of a cell
WO2002063037A2 (en) * 2001-02-02 2002-08-15 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Method for identifying functional nucleic acids
US20050148530A1 (en) 2002-02-20 2005-07-07 Sirna Therapeutics, Inc. RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
WO2003102131A2 (en) * 2002-04-22 2003-12-11 Sirna Therapeutics Inc. Nucleic acid mediated disruption of hiv fusogenic peptide interactions
WO2003070972A2 (en) * 2002-02-20 2003-08-28 Sirna Therapeutics Inc. RNA INTERFERENCE MEDIATED INHIBITION OF CHROMOSOME TRANSLOCATION GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
WO2003070888A2 (en) * 2002-02-20 2003-08-28 Sirna Therapeutics, Inc. Rna interference mediated inhibition of checkpoint kinase-1 (chk-1) gene expression using short interfering nucleic acid
US7517864B2 (en) 2001-05-18 2009-04-14 Sirna Therapeutics, Inc. RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
WO2003070887A2 (en) * 2002-02-20 2003-08-28 Sirna Therapeutics, Inc. RNA INTERFERENCE MEDIATED INHIBITION OF POLYCOMB GROUP PROTEIN EZH2 GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
US9994853B2 (en) 2001-05-18 2018-06-12 Sirna Therapeutics, Inc. Chemically modified multifunctional short interfering nucleic acid molecules that mediate RNA interference
US7109165B2 (en) 2001-05-18 2006-09-19 Sirna Therapeutics, Inc. Conjugates and compositions for cellular delivery
EP3231445A1 (en) 2001-05-18 2017-10-18 Sirna Therapeutics, Inc. Conjugates and compositions for cellular delivery
KR20040022449A (ko) 2001-07-12 2004-03-12 유니버시티 오브 매사추세츠 유전자 불활성화를 매개하는 소형 간섭 ｒｎａ의 생체내제조
US7612194B2 (en) * 2001-07-24 2009-11-03 Monsanto Technology Llc Nucleic acid sequences from Diabrotica virgifera virgifera LeConte and uses thereof
DE60236095D1 (de) 2001-08-31 2010-06-02 Riken Wako PFLANZENSYSTEM ZUR UMFASSENDEN GENFUNKTIONSANALYSE UNTER VERWENDUNG EINER VOLLÄNGEN-cDNA
DE10163098B4 (de) 2001-10-12 2005-06-02 Alnylam Europe Ag Verfahren zur Hemmung der Replikation von Viren
US7745418B2 (en) 2001-10-12 2010-06-29 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting viral replication
US20030150017A1 (en) * 2001-11-07 2003-08-07 Mesa Jose Ramon Botella Method for facilitating pathogen resistance
DE10202419A1 (de) 2002-01-22 2003-08-07 Ribopharma Ag Verfahren zur Hemmung der Expression eines durch eine Chromosomen-Aberration entstandenen Zielgens
US20030166282A1 (en) * 2002-02-01 2003-09-04 David Brown High potency siRNAS for reducing the expression of target genes
US20060009409A1 (en) 2002-02-01 2006-01-12 Woolf Tod M Double-stranded oligonucleotides
EP1478656B1 (en) 2002-02-01 2009-09-16 Life Technologies Corporation Oligonucleotide compositions with enhanced efficiency
US9181551B2 (en) 2002-02-20 2015-11-10 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
AU2003207708A1 (en) 2002-02-20 2003-09-09 Sirna Therapeutics, Inc. Rna interference mediated inhibition of map kinase genes
WO2003070966A2 (en) * 2002-02-20 2003-08-28 Sirna Therapeutics, Inc RNA INTERFERENCE MEDIATED TARGET DISCOVERY AND TARGET VALIDATION USING SHORT INTERFERING NUCLEIC ACID (siNA)
US7667029B2 (en) 2002-02-20 2010-02-23 Sirna Therapeutics, Inc. RNA interference mediated inhibition of checkpoint kinase-1 (CHK-1) gene expression using short interfering nucleic acid (siNA)
AU2003216255A1 (en) * 2002-02-20 2003-09-09 Ribozyme Pharmaceuticals, Inc. RNA INTERFERENCE MEDIATED INHIBITION OF MDR P-GLYCOPROTEIN GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
US9657294B2 (en) 2002-02-20 2017-05-23 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
US20040180438A1 (en) 2002-04-26 2004-09-16 Pachuk Catherine J. Methods and compositions for silencing genes without inducing toxicity
AU2003239851A1 (en) * 2002-05-08 2003-11-11 Xantos Biomedicine Ag Expression constructs for producing double-stranded (ds) rna and the use thereof
AU2003239706A1 (en) * 2002-05-23 2003-12-12 Devgen Nv Method for determining the influence of a compound on cholesterol transport
US20100009856A1 (en) * 2002-06-21 2010-01-14 Sinogenomax Sompany LTD. Randomized dna libraries and double-stranded rna libraries, use and method of production thereof
US7803984B2 (en) * 2002-07-10 2010-09-28 Kansas State University Research Foundation Compositions and methods for controlling plant parasitic nematodes
US7655790B2 (en) 2002-07-12 2010-02-02 Sirna Therapeutics, Inc. Deprotection and purification of oligonucleotides and their derivatives
WO2004015107A2 (en) 2002-08-05 2004-02-19 Atugen Ag Further novel forms of interfering rna molecules
US8729036B2 (en) 2002-08-07 2014-05-20 University Of Massachusetts Compositions for RNA interference and methods of use thereof
CA2497892A1 (en) * 2002-09-04 2004-03-18 Provost, Fellows And Scholars Of The College Of The Holy And Undivided T Rinity Of Queen Elizabeth Near Dublin Compositions and methods for tissue specific or inducible inhibition of gene expression
US7923547B2 (en) 2002-09-05 2011-04-12 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
AU2003298733B2 (en) 2002-11-27 2009-06-18 Agena Bioscience, Inc. Fragmentation-based methods and systems for sequence variation detection and discovery
EP1597361A2 (en) * 2002-12-23 2005-11-23 Devgen NV Kinase sequences useful for developing compounds for the prevention and/or treatment of metabolic diseases and nucleotide sequences encoding such kinase sequences
EP1622572B1 (en) 2003-04-30 2017-12-20 Sirna Therapeutics, Inc. Conjugates and compositions for cellular delivery
IL155783A (en) 2003-05-05 2010-11-30 Technion Res & Dev Foundation Multicellular systems of multi-potential embryonic human stem cells and cancer cells and their use
JP4884224B2 (ja) 2003-05-09 2012-02-29 ディアデクサス インコーポレーテッド Ｏｖｒ１１０抗体組成物および使用方法
JP2006527593A (ja) * 2003-06-17 2006-12-07 デヴゲン エヌブイ 代謝性疾患の予防及び／又は治療のための化合物を開発するために有用なアルコールデヒドロゲナーゼ配列
US9394565B2 (en) 2003-09-05 2016-07-19 Agena Bioscience, Inc. Allele-specific sequence variation analysis
ATE526407T1 (de) * 2003-11-17 2011-10-15 Commw Scient Ind Res Org Insektenresistenz durch inhibierung von genexpression
US7700280B2 (en) 2003-12-31 2010-04-20 The Penn State Research Foundation Methods for assessing cisplatin resistance, disease progression, and treatment efficacy in ovarian cancer
US7858769B2 (en) 2004-02-10 2010-12-28 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using multifunctional short interfering nucleic acid (multifunctional siNA)
US20060019914A1 (en) 2004-02-11 2006-01-26 University Of Tennessee Research Foundation Inhibition of tumor growth and invasion by anti-matrix metalloproteinase DNAzymes
US7622301B2 (en) * 2004-02-24 2009-11-24 Basf Plant Science Gmbh Compositions and methods using RNA interference for control of nematodes
EP2395098B1 (en) 2004-03-26 2015-07-15 Agena Bioscience, Inc. Base specific cleavage of methylation-specific amplification products in combination with mass analysis
US7608394B2 (en) * 2004-03-26 2009-10-27 Sequenom, Inc. Methods and compositions for phenotype identification based on nucleic acid methylation
CA2562038C (en) 2004-04-02 2017-04-25 The Regents Of The University Of California Methods and compositions for treating and preventing disease associated with .alpha.v.beta.5 integrin
CA2762011C (en) 2004-04-09 2019-05-07 Monsanto Technology Llc Compositions and methods for control of insect infestations in plants
CA2557532A1 (en) 2004-04-23 2005-11-10 Angela M. Christiano Inhibition of hairless protein mrna
US10508277B2 (en) 2004-05-24 2019-12-17 Sirna Therapeutics, Inc. Chemically modified multifunctional short interfering nucleic acid molecules that mediate RNA interference
EP2298896A1 (en) 2004-06-22 2011-03-23 The Board of Trustees of the University of Illinois Methods of inhibiting tumor cell proliferation with FOXM1 siRNA
US7968762B2 (en) 2004-07-13 2011-06-28 Van Andel Research Institute Immune-compromised transgenic mice expressing human hepatocyte growth factor (hHGF)
EP1782321A4 (en) 2004-07-23 2009-11-04 Univ North Carolina METHOD AND MATERIALS FOR DETERMINING PAIN SENSITIVITY AND PREDICTING AND TREATING SUFFERING INTERFERENCE
US20080255065A1 (en) 2004-08-18 2008-10-16 Genesense Technologies, Inc. Small Interfering Rna Molecules Against Ribonucleotide Reductase and Uses Thereof
US8158414B2 (en) 2004-09-24 2012-04-17 J.R. Simplot Company Gene silencing
US20060247197A1 (en) 2004-10-04 2006-11-02 Van De Craen Marc Method for down-regulating gene expression in fungi
US7576261B2 (en) * 2004-10-13 2009-08-18 University Of Georgia Research Foundation, Inc. Nematode resistant transgenic plants
CN101107362A (zh) 2004-10-21 2008-01-16 文甘扎公司 用于赋予对植物病害生物和植物病原体抗性的方法和材料
WO2006045591A2 (en) * 2004-10-25 2006-05-04 Devgen N.V. Method and constructs for delivering double stranded rna to pest organisms
WO2006046148A2 (en) 2004-10-25 2006-05-04 Devgen Nv Rna constructs
US7964195B2 (en) 2005-01-07 2011-06-21 Diadexus, Inc. Ovr110 antibody compositions and methods of use
US8088976B2 (en) * 2005-02-24 2012-01-03 Monsanto Technology Llc Methods for genetic control of plant pest infestation and compositions thereof
DE202005004135U1 (de) * 2005-03-11 2005-05-19 Klocke Verpackungs-Service Gmbh Mehrkomponentenverpackung mit Applikator
CA2603730A1 (en) 2005-03-31 2006-10-05 Calando Pharmaceuticals, Inc. Inhibitors of ribonucleotide reductase subunit 2 and uses thereof
JP2008540571A (ja) 2005-05-12 2008-11-20 ウィスコンシン・アルムニ・リサーチ・ファウンデーション Ｐｉｎ１の遮断は活性化した免疫細胞によるサイトカイン産生を防ぐ
CN101213301B (zh) 2005-05-31 2013-02-27 德福根有限公司 用于防治昆虫和蜘蛛类动物的RNAi
US8703769B2 (en) 2005-07-15 2014-04-22 The University Of North Carolina At Chapel Hill Use of EGFR inhibitors to prevent or treat obesity
AP2008004416A0 (en) 2005-09-16 2008-04-30 Monsanto Technology Llc Methods for genetic control of insect infestationsin plants and compositions thereof
AU2006335978B2 (en) 2005-09-16 2014-02-20 Devgen Nv Methods for controlling pests using RNAI
PT2295584E (pt) 2005-09-16 2015-09-22 Devgen Nv Métodos com base em plantas transgénicas para infestações em plantas utilizando arn de interferência
CN101268194A (zh) 2005-09-20 2008-09-17 巴斯福植物科学有限公司 使用ta-siRNA调控基因表达的方法
US9286469B2 (en) * 2005-12-16 2016-03-15 Cisco Technology, Inc. Methods and apparatus providing computer and network security utilizing probabilistic signature generation
CA2636070A1 (en) * 2006-01-06 2007-08-02 North Carolina State University Cyst nematode resistant transgenic plants
US8906876B2 (en) 2006-01-12 2014-12-09 Devgen Nv Methods for controlling pests using RNAi
BRPI0706266A2 (pt) 2006-01-12 2009-02-25 Devgen Nv mÉtodos para controle de pragas usando a rnai
CA2633576A1 (en) 2006-01-12 2007-07-19 Devgen N.V. Dsrna as insect control agent
US20080022423A1 (en) * 2006-02-03 2008-01-24 Monsanto Technology Llc IN PLANTA RNAi CONTROL OF FUNGI
CA2637665A1 (en) 2006-02-10 2007-08-23 Monsanto Technology Llc Identification and use of target genes for control of the plant parasitic nematodes heterodera glycines
EP2426206B8 (en) * 2006-02-13 2018-10-31 Monsanto Technology LLC Selecting and stabilizing dsRNA constructs
WO2007104570A2 (en) * 2006-03-16 2007-09-20 Devgen N.V. Nematode control
US8968702B2 (en) 2006-03-30 2015-03-03 Duke University Inhibition of HIF-1 activation for anti-tumor and anti-inflammatory responses
PL216037B1 (pl) * 2006-06-09 2014-02-28 Inst Biotechnologii I Antybiotykow Kaseta ekspresyjna, zastosowanie kasety ekspresyjnej, wektor, komórka gospodarza oraz sposób otrzymywania polipeptydu
EP2471809B1 (en) 2006-07-11 2015-09-02 University Of Medicine And Dentistry Of New Jersey Proteins, nucleic acids encoding the same and associated methods of use
US20100105610A1 (en) 2006-07-28 2010-04-29 Children's Memorial Hospital Methods of Inhibiting Tumor Cell Aggressiveness Using the Microenvironment of Human Embryonic Stem Cells
AU2007325283B2 (en) 2006-11-27 2012-08-30 Diadexus, Inc. Ovr110 antibody compositions and methods of use
CN101195821A (zh) * 2006-12-04 2008-06-11 中国科学院上海生命科学研究院 利用RNAi技术改良植物抗虫性的方法
EP2097448A4 (en) 2006-12-22 2010-07-21 Univ Utah Res Found PROCEDURE FOR THE EVIDENCE OF EYE DISEASES AND SUFFERINGS AND THEIR TREATMENT
EP2117305A4 (en) 2007-01-26 2011-03-30 Univ Louisville Res Found MODIFICATION OF EXOSOMAL COMPONENTS FOR USE AS A VACCINATE
US20080184391A1 (en) * 2007-01-29 2008-07-31 Kuppuswamy Subramaniam Pathogen resistant transgenic plants, associated nucleic acids and techniques involving the same
WO2008103643A1 (en) 2007-02-20 2008-08-28 Monsanto Technology, Llc Invertebrate micrornas
BRPI0809130A8 (pt) 2007-03-21 2021-11-03 Brookhaven Science Ass Llc Composições combinadas hairpin-antissenso e métodos para modulação da expressão
EP2377952A1 (en) 2007-04-26 2011-10-19 Ludwig Institute For Cancer Research Methods for diagnosing and treating astrocytomas
EP2155860B1 (en) 2007-05-03 2014-08-27 The Brigham and Women's Hospital, Inc. Multipotent stem cells and uses thereof
US8097422B2 (en) 2007-06-20 2012-01-17 Salk Institute For Biological Studies Kir channel modulators
US20110111496A1 (en) * 2007-06-29 2011-05-12 Chiang Li BACTERIA-MEDIATED GENE MODULATION VIA microRNA MACHINERY
US9689031B2 (en) 2007-07-14 2017-06-27 Ionian Technologies, Inc. Nicking and extension amplification reaction for the exponential amplification of nucleic acids
WO2009012263A2 (en) 2007-07-18 2009-01-22 The Trustees Of Columbia University In The City Of New York Tissue-specific micrornas and compositions and uses thereof
US20110131668A1 (en) 2007-08-14 2011-06-02 Commonwealth Scientific And Industrial Research Organisation Improved gene silencing methods
KR101142209B1 (ko) 2007-09-22 2012-05-04 재단법인서울대학교산학협력재단 섭취 ＲＮＡｉ를 이용한 꼬마선충에서 두 유전자의동시발현 억제방법
US7968525B1 (en) 2007-12-03 2011-06-28 University Of Florida Research Foundation, Inc. Use of RNA interference to validate new termiticide target sites and a method of termite control
KR20100127880A (ko) 2008-04-04 2010-12-06 카란도 파마슈티칼즈, 인코포레이티드 Ｅｐａｓ1 억제제의 조성물 및 용도
WO2009126896A2 (en) 2008-04-10 2009-10-15 Monsanto Technology Llc Methods and compositions for root knot nematode control
GB0807018D0 (en) 2008-04-17 2008-05-21 Fusion Antibodies Ltd Antibodies and treatment
EP2727996A1 (en) 2008-11-06 2014-05-07 The Johns-Hopkins University Treatment of chronic inflammatory respiratory disorders with NP1 inhibitors
EP2687609B1 (en) 2008-11-10 2017-01-04 The United States of America, as represented by The Secretary, Department of Health and Human Services Method for treating solid tumor
DK2379722T3 (da) 2008-12-16 2017-01-02 C-Lecta Gmbh Ekspressionsvektor
WO2010074783A1 (en) 2008-12-23 2010-07-01 The Trustees Of Columbia University In The City Of New York Phosphodiesterase inhibitors and uses thereof
JP2012513464A (ja) 2008-12-23 2012-06-14 ザ トラスティーズ オブ コロンビア ユニヴァーシティ イン ザ シティ オブ ニューヨーク ホスホジエステラーゼ阻害剤及びその使用
JP2012520685A (ja) 2009-03-19 2012-09-10 メルク・シャープ・エンド・ドーム・コーポレイション 低分子干渉核酸（ｓｉＮＡ）を用いたＧＡＴＡ結合タンパク質３（ＧＡＴＡ３）遺伝子発現のＲＮＡ干渉媒介性阻害
KR20110137799A (ko) 2009-03-19 2011-12-23 머크 샤프 앤드 돔 코포레이션 짧은 간섭 핵산 (ｓｉＮＡ) 서열 목록을 사용한 ＢＴＢ 및 ＣＮＣ 상동체 1, 염기성 류신 지퍼 전사 인자 1 (ＢＡＣＨ1) 유전자 발현의 ＲＮＡ 간섭 매개 억제
WO2010107952A2 (en) 2009-03-19 2010-09-23 Merck Sharp & Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF CONNECTIVE TISSUE GROWTH FACTOR (CTGF) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
JP2012520686A (ja) 2009-03-19 2012-09-10 メルク・シャープ・エンド・ドーム・コーポレイション 低分子干渉核酸（ｓｉＮＡ）を用いたシグナル伝達性転写因子６（ＳＴＡＴ６）遺伝子発現のＲＮＡ干渉媒介性阻害
SG174581A1 (en) 2009-03-27 2011-10-28 Merck Sharp & Dohme RNA INTERFERENCE MEDIATED INHIBITION OF THE INTERCELLULAR ADHESION MOLECULE 1 (ICAM-1)GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
WO2010111464A1 (en) 2009-03-27 2010-09-30 Merck Sharp & Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF APOPTOSIS SIGNAL-REGULATING KINASE 1 (ASK1) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
WO2010111490A2 (en) 2009-03-27 2010-09-30 Merck Sharp & Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF THE THYMIC STROMAL LYMPHOPOIETIN (TSLP) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
US20120004281A1 (en) 2009-03-27 2012-01-05 Merck Sharp & Dohme Corp RNA Interference Mediated Inhibition of the Nerve Growth Factor Beta Chain (NGFB) Gene Expression Using Short Interfering Nucleic Acid (siNA)
JP2012521763A (ja) 2009-03-27 2012-09-20 メルク・シャープ・エンド・ドーム・コーポレイション 低分子干渉核酸（ｓｉＮＡ）を用いたシグナル伝達性転写因子１（ＳＴＡＴ１）遺伝子発現のＲＮＡ干渉媒介性阻害
US20100257634A1 (en) * 2009-04-03 2010-10-07 Venganza Inc. Bioassay for gene silencing constructs
US8283332B2 (en) 2009-04-17 2012-10-09 University Of Louisville Research Foundation, Inc. PFKFB4 inhibitors and methods of using the same
EP2258858A1 (en) 2009-06-05 2010-12-08 Universitätsklinikum Freiburg Transgenic LSD1 animal model for cancer
PL2453923T3 (pl) 2009-07-14 2016-06-30 Mayo Found Medical Education & Res Niekowalencyjne dostarczanie aktywnych czynników przez barierę krew-mózg przy udziale peptydów
US10087252B2 (en) 2009-07-24 2018-10-02 The Regents Of The University Of California Methods and compositions for treating and preventing disease associated with αvβ5 integrin
MX351822B (es) 2009-08-28 2017-10-30 Du Pont Composicicones y métodos para controlar plagas de insectos.
US9163240B2 (en) 2009-12-07 2015-10-20 The Johns Hopkins University SR-BI mutation as a predictor of low progesterone levels and poor fetal viability during pregnancy
EP2509991B1 (en) 2009-12-09 2015-11-11 Nitto Denko Corporation Modulation of hsp47 expression
ES2764999T3 (es) 2009-12-10 2020-06-05 Univ Columbia Activadores de histona acetiltransferasa y usos de los mismos
US10640457B2 (en) 2009-12-10 2020-05-05 The Trustees Of Columbia University In The City Of New York Histone acetyltransferase activators and uses thereof
EP2513309A2 (en) 2009-12-18 2012-10-24 Novartis AG Organic compositions to treat hsf1-related diseases
EP3721943A1 (en) 2009-12-23 2020-10-14 Novartis AG Lipids, lipid compositions and methods of using them
EP2529033B1 (en) 2010-01-26 2017-05-24 National Jewish Health Methods for risk prediction, diagnosis, prognosis of pulmonary disorders
CN102770767A (zh) 2010-02-10 2012-11-07 诺瓦提斯公司 用于肌肉生长的方法和组合物
EP2571987B1 (en) 2010-05-21 2017-03-01 Peptimed, Inc. Reagents for treating cancer
GB201009601D0 (en) 2010-06-08 2010-07-21 Devgen Private Ltd Method for down-grading gene expression in fungi
WO2011163466A1 (en) 2010-06-23 2011-12-29 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Regulation of skin pigmentation by neuregulin-1 (nrg-1)
US8518907B2 (en) 2010-08-02 2013-08-27 Merck Sharp & Dohme Corp. RNA interference mediated inhibition of catenin (cadherin-associated protein), beta 1 (CTNNB1) gene expression using short interfering nucleic acid (siNA)
JP2013537423A (ja) 2010-08-17 2013-10-03 メルク・シャープ・エンド・ドーム・コーポレイション 低分子干渉核酸（ｓｉＮＡ）を用いたＢ型肝炎ウイルス（ＨＢＶ）遺伝子発現のＲＮＡ干渉媒介性阻害
KR20130137160A (ko) 2010-08-24 2013-12-16 머크 샤프 앤드 돔 코포레이션 내부의 비－핵산 스페이서를 함유하는 단일－가닥 ＲＮＡｉ 작용제
WO2012027467A1 (en) 2010-08-26 2012-03-01 Merck Sharp & Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF PROLYL HYDROXYLASE DOMAIN 2 (PHD2) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
US20140134231A1 (en) 2010-10-11 2014-05-15 Sanford-Burnham Medical Research Institute Mir-211 expression and related pathways in human melanoma
BR112013009196A2 (pt) 2010-10-15 2020-08-25 The Trustees Of Columbia University In The City Of New York usos de polipeptídeo para redução da aquisição de ácido graxo e da ingestão de alimento, bem como para promoção de saciedade relacionados à obesidade
EP2632472B1 (en) 2010-10-29 2017-12-13 Sirna Therapeutics, Inc. Rna interference mediated inhibition of gene expression using short interfering nucleic acids (sina)
EP2635308A2 (en) 2010-11-01 2013-09-11 Peptimed, Inc. Compositions of a peptide targeting system for treating cancer
US9198911B2 (en) 2010-11-02 2015-12-01 The Trustees Of Columbia University In The City Of New York Methods for treating hair loss disorders
CN103370076A (zh) 2010-11-02 2013-10-23 纽约市哥伦比亚大学托管会 治疗毛发脱落疾病的方法
US9150926B2 (en) 2010-12-06 2015-10-06 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Diagnosis and treatment of adrenocortical tumors using human microRNA-483
EP2649181B1 (en) 2010-12-06 2016-04-27 Quark Pharmaceuticals, Inc. Double stranded oligonucleotide compounds comprising positional modifications
JP6616057B2 (ja) 2010-12-22 2019-12-04 ザ トラスティーズ オブ コロンビア ユニヴァーシティ イン ザ シティ オブ ニューヨーク ヒストンアセチル基転移酵素モジュレーターおよびその使用
CA2828002A1 (en) 2011-03-03 2012-09-07 Quark Pharmaceuticals, Inc. Compositions and methods for treating lung disease and injury
US10196637B2 (en) 2011-06-08 2019-02-05 Nitto Denko Corporation Retinoid-lipid drug carrier
TWI658830B (zh) 2011-06-08 2019-05-11 日東電工股份有限公司 Ｈｓｐ47表現調控強化用類視色素脂質體
EP3072555B1 (en) 2011-09-02 2020-03-25 The Trustees of Columbia University in the City of New York Mk2/3 inhibitors to treat metabolic disturbances of obesity
US9352312B2 (en) 2011-09-23 2016-05-31 Alere Switzerland Gmbh System and apparatus for reactions
BR112014008862A2 (pt) 2011-10-14 2018-08-07 Genentech Inc anticorpo isolado que se liga à htra1, ácido nucleico isolado, célula hospedeira, imunoconjugado, formulação farmacêutica, métodos e usos
AU2012325997C1 (en) 2011-10-18 2018-07-05 Dicerna Pharmaceuticals, Inc. Amine cationic lipids and uses thereof
JP6118331B2 (ja) 2011-11-03 2017-04-19 クォーク ファーマシューティカルズ インコーポレーティッドＱｕａｒｋ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． 神経保護のための方法および組成物
HRP20181976T1 (hr) 2012-03-29 2019-01-25 The Trustees Of Columbia University In The City Of New York Postupci za liječenje poremećaja gubitka kose
WO2013158966A1 (en) 2012-04-20 2013-10-24 Futuragene Israel Ltd. Bronze bug control agents
WO2013163085A2 (en) 2012-04-23 2013-10-31 Futuragene Israel Ltd. Glycaspis brimblecombei control agents
EP3358013B1 (en) 2012-05-02 2020-06-24 Sirna Therapeutics, Inc. Short interfering nucleic acid (sina) compositions
US20150175979A1 (en) 2012-07-23 2015-06-25 La Jolla Institute For Allergy And Immunology Ptprs and proteoglycans in autoimmune disease
US20150259701A1 (en) 2012-10-03 2015-09-17 Futuragene Israel Ltd. Gall wasp control agents
WO2014058915A2 (en) 2012-10-08 2014-04-17 St. Jude Children's Research Hospital Therapies based on control of regulatory t cell stability and function via a neuropilin-1:semaphorin axis
US9920316B2 (en) 2013-03-14 2018-03-20 Pioneer Hi-Bred International, Inc. Compositions and methods to control insect pests
KR20150129847A (ko) 2013-03-15 2015-11-20 더 트러스티스 오브 컬럼비아 유니버시티 인 더 시티 오브 뉴욕 융합 단백질 및 이들의 방법
EP2810952A1 (en) 2013-06-03 2014-12-10 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Novel pest control methods
WO2015002969A1 (en) 2013-07-03 2015-01-08 City Of Hope Anticancer combinations
EP3055426B1 (en) 2013-10-09 2019-06-19 The United States of America as represented by The Secretary Department of Health and Human Services Detection of hepatitis delta virus (hdv) for the diagnosis and treatment of sjögren's syndrome and lymphoma
AU2014346457A1 (en) 2013-11-11 2016-06-02 Sirna Therapeutics, Inc. Systemic delivery of myostatin short interfering nucleic acids (siNA) conjugated to a lipophilic moiety
US9682123B2 (en) 2013-12-20 2017-06-20 The Trustees Of Columbia University In The City Of New York Methods of treating metabolic disease
JP6372930B2 (ja) 2013-12-27 2018-08-15 国立大学法人高知大学 悪性腫瘍の治療薬
CN106794141B (zh) 2014-07-16 2021-05-28 诺华股份有限公司 将核酸包封在脂质纳米粒主体中的方法
WO2016059187A1 (en) * 2014-10-16 2016-04-21 Universite De Strasbourg Method of capturing and identifying novel rnas
EP3218497A1 (en) 2014-11-12 2017-09-20 NMC Inc. Transgenic plants with engineered redox sensitive modulation of photosynthetic antenna complex pigments and methods for making the same
EP3778644A3 (en) 2014-12-23 2021-06-02 The Trustees of Columbia University in the City of New York Fgfr-tacc fusion proteins and methods thereof
US10264976B2 (en) 2014-12-26 2019-04-23 The University Of Akron Biocompatible flavonoid compounds for organelle and cell imaging
WO2016145008A2 (en) 2015-03-09 2016-09-15 University Of Kentucky Research Foundation Mirna for treatment of breast cancer
WO2016145003A1 (en) 2015-03-09 2016-09-15 University Of Kentucky Research Foundation Rna nanoparticle for treatment of gastric cancer
CN107531740B (zh) 2015-03-09 2021-03-19 肯塔基大学研究基金会 用于脑肿瘤治疗的rna纳米颗粒
US11279768B1 (en) 2015-04-03 2022-03-22 Precision Biologics, Inc. Anti-cancer antibodies, combination therapies, and uses thereof
WO2016168784A2 (en) 2015-04-17 2016-10-20 University Of Kentucky Research Foundation Rna nanoparticles and method of use thereof
US20180156807A1 (en) 2015-04-29 2018-06-07 New York University Method for treating high-grade gliomas
EP3313420B1 (en) 2015-06-25 2024-03-13 The Children's Medical Center Corporation Methods and compositions relating to hematopoietic stem cell expansion, enrichment, and maintenance
US10072065B2 (en) 2015-08-24 2018-09-11 Mayo Foundation For Medical Education And Research Peptide-mediated delivery of immunoglobulins across the blood-brain barrier
AU2016321298A1 (en) 2015-09-09 2018-03-29 The Trustees Of Columbia University In The City Of New York Reduction of ER-MAM localized APP-C99 and methods of treating Alzheimer's Disease
WO2017059118A1 (en) 2015-09-29 2017-04-06 Duke University Compositions and methods for identifying and treating dystonia disorders
PH12022550450A1 (en) 2015-10-30 2023-05-03 Genentech Inc Anti-htra1 antibodies and methods of use thereof
JP6457704B2 (ja) 2015-12-13 2019-01-23 日東電工株式会社 高活性及びオフターゲット削減のためのｓｉＲＮＡ構造
US11072777B2 (en) 2016-03-04 2021-07-27 University Of Louisville Research Foundation, Inc. Methods and compositions for ex vivo expansion of very small embryonic-like stem cells (VSELs)
EP4049665B1 (en) 2016-03-15 2025-03-12 The Children's Medical Center Corporation Methods and compositions relating to hematopoietic stem cell expansion
US10883108B2 (en) 2016-03-31 2021-01-05 The Schepens Eye Research Institute, Inc. Endomucin inhibitor as an anti-angiogenic agent
EP3516062A1 (en) 2016-09-21 2019-07-31 Alnylam Pharmaceuticals, Inc. Myostatin irna compositions and methods of use thereof
CN107858405B (zh) * 2017-10-12 2021-09-24 华南农业大学 一种测定外源dsRNA对瓢虫毒性影响的方法
US20210162007A1 (en) 2018-04-09 2021-06-03 President And Fellows Of Harvard College Modulating nuclear receptors and methods of using same
CN109183158B (zh) * 2018-08-31 2021-11-23 中国烟草总公司郑州烟草研究院 一种全长转录因子酵母单杂交文库的构建方法
CN109266677B (zh) * 2018-08-31 2021-11-23 中国烟草总公司郑州烟草研究院 一种全长转录因子酵母双杂交文库的构建方法
EP3853250A4 (en) 2018-09-19 2022-06-08 La Jolla Institute for Immunology Ptprs and proteoglycans in rheumatoid arthritis
PT3880212T (pt) 2018-11-16 2024-02-08 Nitto Denko Corp Formulação e métodos de administração de rna de interferência para tumores malignos
EP3907504A4 (en) * 2019-01-04 2022-11-30 Kyoto University TEST METHOD FOR UC AND PRIMARY SCLEROSING CHOLANGITIS
US12215382B2 (en) 2019-03-01 2025-02-04 The General Hospital Corporation Liver protective MARC variants and uses thereof
CN110229839B (zh) * 2019-06-04 2021-06-08 中国农业大学 一种提升大肠杆菌dsRNA表达产率的方法
CN110804088A (zh) * 2019-11-18 2020-02-18 维塔恩(广州)医药有限公司 巨细胞病毒相关抗原短肽及其应用
CN110746497A (zh) * 2019-11-18 2020-02-04 维塔恩(广州)医药有限公司 肺炎衣原体相关抗原短肽及其应用
EP3825408A1 (en) 2019-11-19 2021-05-26 FRAUNHOFER-GESELLSCHAFT zur Förderung der angewandten Forschung e.V. Methods of multi-species insect pest control
US20230279394A1 (en) 2019-12-18 2023-09-07 Novartis Ag Compositions and methods for the treatment of hemoglobinopathies
CA3164832A1 (en) 2019-12-18 2021-06-24 Novartis Ag 3-(5-methoxy-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
US12344665B2 (en) 2020-01-08 2025-07-01 Regeneron Pharmaceuticals, Inc. Treatment of fibrodysplasia ossificans progressiva by administration of an anti-activin a antibody
WO2021150300A1 (en) 2020-01-22 2021-07-29 Massachusetts Institute Of Technology Inducible tissue constructs and uses thereof
WO2021173965A1 (en) 2020-02-28 2021-09-02 Massachusetts Institute Of Technology Identification of variable influenza residues and uses thereof
CN111560651B (zh) * 2020-05-22 2021-09-07 江苏省疾病预防控制中心(江苏省公共卫生研究院) 一种制备双链rna测序文库的方法
TW202241479A (zh) 2020-12-30 2022-11-01 美商安迅生物製藥公司 遞送外來抗原之溶瘤病毒及表現靶向外來抗原之嵌合受體之經工程化免疫細胞之組合療法
WO2022269518A2 (en) 2021-06-23 2022-12-29 Novartis Ag Compositions and methods for the treatment of hemoglobinopathies
US20250084420A1 (en) 2021-08-02 2025-03-13 Universite De Montpellier Compositions and methods for treating cmt1a or cmt1e diseases with rnai molecules targeting pmp22
CN113533007B (zh) * 2021-08-06 2023-11-24 青岛瑞斯凯尔生物科技有限公司 一种抗体染色标记装置及其方法
CA3232968A1 (en) 2021-10-14 2023-04-20 Jasper Williams Immune cells having co-expressed shrnas and logic gate systems
AU2023343318A1 (en) 2022-09-13 2025-04-10 Arsenal Biosciences, Inc. Immune cells having co-expressed tgfbr shrnas
WO2024059824A2 (en) 2022-09-16 2024-03-21 Arsenal Biosciences, Inc. Immune cells with combination gene perturbations
US12257304B2 (en) 2023-03-03 2025-03-25 Arsenal Biosciences, Inc. Systems targeting PSMA and CA9

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US589801A (en) * 1897-09-07 woltereck
ATE202139T1 (de) 1985-03-21 2001-06-15 Johnston Stephen Ph D Von parasit gewonnener widerstand
US6608241B1 (en) 1985-10-29 2003-08-19 Monsanto Technology Llc Protection of plants against viral infection
IL81737A (en) 1986-03-28 1992-11-15 Calgene Inc Regulation of gene expression in plant cells
US5017488A (en) * 1986-04-01 1991-05-21 University Of Medicine And Dentistry Of New Jersey Highly efficient dual T7/T3 promoter vector PJKF16 and dual SP6/T3 promoter vector PJFK15
US4970168A (en) * 1989-01-27 1990-11-13 Monsanto Company Virus-resistant plants
WO1990014090A1 (en) * 1989-05-19 1990-11-29 Hem Research, Inc. SHORT THERAPEUTIC dsRNA OF DEFINED STRUCTURE
HUT57265A (en) 1989-11-03 1991-11-28 Zaadunie Bv Process for producing plants of diminished infection-sensitivity
US5837848A (en) * 1990-03-16 1998-11-17 Zeneca Limited Root-specific promoter
CA2077686A1 (en) * 1990-03-30 1991-10-01 Philip Leder Binary genetic system to control expression of a transgene in a transgenic animal
US5831011A (en) * 1990-07-27 1998-11-03 Mycogen Corporation Bacillus thuringiensis genes encoding nematode-active toxins
US5459252A (en) * 1991-01-31 1995-10-17 North Carolina State University Root specific gene promoter
DE69333333T2 (de) 1992-03-20 2004-09-23 Max Planck Gesellschaft zur Förderung der Wissenschaften e.V. Auf fungus reagierendes chimaeres gen
DE4234131C2 (de) * 1992-10-09 1995-08-24 Max Planck Gesellschaft Transgener pathogen-resistenter Organismus
CA2088379A1 (en) * 1993-01-29 1994-07-30 University Of British Columbia Biological systems incorporating stress-inducible genes and reporter constructs for environmental biomonitoring and toxicology
IL104830A (en) * 1993-02-23 2001-01-28 Yissum Res Dev Co A chimeric plasmid containing a non-structural gene for the protease of the potato virus and its various uses
DE4317845A1 (de) 1993-05-28 1994-12-01 Bayer Ag Desoxyribonukleinsäuren
US5482845A (en) * 1993-09-24 1996-01-09 The Trustees Of Columbia University In The City Of New York Method for construction of normalized cDNA libraries
CA2192689A1 (en) * 1994-06-15 1995-12-21 Paul B. Fisher Method to identify tumor suppressor genes
US5691140A (en) * 1995-05-18 1997-11-25 New England Biolabs, Inc. Bidirectional in vitro transcription vectors utilizing a single RNA polymerase for both directions
GB9510944D0 (en) * 1995-05-31 1995-07-26 Bogaert Thierry Assays and processes for the identification of compounds which control cell behaviour,the compounds identified and their use in the control of cell behaviour
KR19990022157A (ko) * 1995-06-02 1999-03-25 앰앤드이 바이오테크 아/에스 생물학적으로 활성인 펩티드 및 핵산을 확인하는 방법
US5679551A (en) * 1995-10-31 1997-10-21 Board Of Regents, The University Of Texas System Unique double-stranded RNAS associated with the Trichomonas vaginalis virus
US5898031A (en) * 1996-06-06 1999-04-27 Isis Pharmaceuticals, Inc. Oligoribonucleotides for cleaving RNA
DE19631919C2 (de) * 1996-08-07 1998-07-16 Deutsches Krebsforsch Anti-Sinn-RNA mit Sekundärstruktur
DK1493817T3 (da) * 1996-08-09 2011-03-28 Keygene Nv Resistens over for planteskadegørere
PL332311A1 (en) * 1996-09-18 1999-08-30 Christian Jung Immunity gene against nematodes
CA2267780A1 (en) 1996-10-03 1998-04-09 Hajime Kato Method for hydrocarbon steam reforming
DE69704960T2 (de) 1996-12-18 2002-03-28 Exxonmobil Chemical Patents Inc., Baytown Kompatibilisierte polymermischungen hergestellt unter verwendung eines multifunktionellen mittels
GB9703146D0 (en) 1997-02-14 1997-04-02 Innes John Centre Innov Ltd Methods and means for gene silencing in transgenic plants
US6506559B1 (en) * 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
AUPP249298A0 (en) * 1998-03-20 1998-04-23 Ag-Gene Australia Limited Synthetic genes and genetic constructs comprising same I
ATE507299T1 (de) * 1998-04-08 2011-05-15 Commw Scient Ind Res Org Verfahren und mittel zum erhalt von veränderten phänotypen
AR020078A1 (es) * 1998-05-26 2002-04-10 Syngenta Participations Ag Metodo para alterar la expresion de un gen objetivo en una celula de planta
GB9814536D0 (en) 1998-07-03 1998-09-02 Devgen Nv Characterisation of gene function using double stranded rna inhibition
GB9827152D0 (en) 1998-07-03 1999-02-03 Devgen Nv Characterisation of gene function using double stranded rna inhibition
AUPR621501A0 (en) 2001-07-06 2001-08-02 Commonwealth Scientific And Industrial Research Organisation Delivery of ds rna
AP2008004416A0 (en) 2005-09-16 2008-04-30 Monsanto Technology Llc Methods for genetic control of insect infestationsin plants and compositions thereof

Also Published As

Publication number Publication date
CA2789083A1 (en) 2000-01-13
CA2332619C (en) 2012-12-11
CA2789083C (en) 2016-03-15
EP1093526A2 (en) 2001-04-25
BR9911802A (pt) 2002-01-22
NO20010019L (no) 2001-03-05
US20040187170A1 (en) 2004-09-23
HU230602B1 (hu) 2017-02-28
EP1484415A3 (en) 2008-02-13
WO2000001846A3 (en) 2000-06-15
GB2370275A (en) 2002-06-26
NO327729B1 (no) 2009-09-14
IL181727A0 (en) 2007-07-04
US8114980B2 (en) 2012-02-14
US20030061626A1 (en) 2003-03-27
EP1197567A3 (en) 2003-01-02
DE29924299U1 (de) 2002-09-12
IL140467A0 (en) 2002-02-10
KR20010074639A (ko) 2001-08-04
ZA200007653B (en) 2002-09-19
EP2374901A1 (en) 2011-10-12
PT1484415E (pt) 2009-07-27
PT1197567E (pt) 2009-04-09
EP1197567A2 (en) 2002-04-17
ES2320527T3 (es) 2009-05-25
HUP0103571A3 (en) 2006-01-30
DK1197567T4 (en) 2015-12-07
CN1900319A (zh) 2007-01-24
DK1197567T3 (da) 2009-05-04
WO2000001846A2 (en) 2000-01-13
IN2006DE03568A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2007-08-31
KR100563295B1 (ko) 2006-03-27
MX234065B (es) 2006-02-01
CN1198938C (zh) 2005-04-27
JP2014058514A (ja) 2014-04-03
IL181727A (en) 2015-08-31
EP1197567B2 (en) 2015-10-07
HK1029142A1 (en) 2001-03-23
DE69940219D1 (de) 2009-02-12
IS5802A (is) 2001-01-02
IN2001DE00006A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2007-02-09
CZ303494B6 (cs) 2012-10-24
GB0206600D0 (en) 2002-05-01
PL216779B1 (pl) 2014-05-30
HUP0103571A2 (hu) 2002-01-28
JP2002519072A (ja) 2002-07-02
NO20010019D0 (no) 2001-01-02
EP2045336A2 (en) 2009-04-08
PL201425B1 (pl) 2009-04-30
CY1109324T1 (el) 2014-07-02
JP2009112311A (ja) 2009-05-28
ES2320527T5 (es) 2015-11-16
EP1484415A2 (en) 2004-12-08
DE29924298U1 (de) 2002-09-12
US20040133943A1 (en) 2004-07-08
GB2349885A (en) 2000-11-15
EP2045336A3 (en) 2009-06-10
PL213379B1 (pl) 2013-02-28
GB9827152D0 (en) 1999-02-03
DK1484415T3 (da) 2009-10-12
EP1197567B1 (en) 2008-12-31
AU769223B2 (en) 2004-01-22
ATE433500T1 (de) 2009-06-15
RU2240349C2 (ru) 2004-11-20
KR20060071438A (ko) 2006-06-26
MXPA00012955A (es) 2002-04-10
IL140467A (en) 2007-07-04
CN1323354A (zh) 2001-11-21
EP1484415B1 (en) 2009-06-10
KR20040066200A (ko) 2004-07-23
IS2816B (is) 2012-11-15
GB2370275B (en) 2002-11-27
KR20070041607A (ko) 2007-04-18
CN1657620A (zh) 2005-08-24
CY1108920T1 (el) 2014-07-02
PL347978A1 (en) 2002-05-06
GB2349885B (en) 2003-01-29
JP5847776B2 (ja) 2016-01-27
GB0020485D0 (en) 2000-10-11
GB2362885B (en) 2002-07-31
DE1093526T1 (de) 2001-10-11
CZ200114A3 (en) 2001-06-13
ATE419383T1 (de) 2009-01-15
DE69940984D1 (de) 2009-07-23
GB2362885A (en) 2001-12-05
CA2332619A1 (en) 2000-01-13
NZ509182A (en) 2004-01-30
ES2327334T3 (es) 2009-10-28
CZ304897B6 (cs) 2015-01-07
AU4907999A (en) 2000-01-24
GB0118514D0 (en) 2001-09-19

Similar Documents

Publication Publication Date Title
JP4353639B2 (ja) 二本鎖ｒｎａ阻害を用いる遺伝子機能の評価
Ryder et al. Transposable elements as tools for genomics and genetics in Drosophila
EP1187938B1 (en) Method of regulated expression of transgenes in the germline of caenorhabditis elegans
US7005423B1 (en) Characterization of gene function using double stranded RNA inhibition
AU2004200852B2 (en) Characterisation of gene function using double stranded RNA inhibition
Morton ZINC FINGER NUCLEASE-INDUCED DOUBLE-STRAND BREAKS MEDIATE

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20060703

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080904

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20080904

A975 Report on accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A971005

Effective date: 20081001

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20081007

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090107

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20090224

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090522

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20090630

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20090728

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20120807

Year of fee payment: 3

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20130807

Year of fee payment: 4

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees